Engineered hybrid cell membrane nanosystems for treating cardiovascular diseases
Cardiovascular diseases (CVDs) continue to represent a major challenge to global health, highlighting the urgent need for innovative treatment approaches. As a growing interdisciplinary field, nanotechnology has demonstrated significant potential for clinical applications. Nanomedicine development p...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006425005629 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849433406170988544 |
|---|---|
| author | He Lu Yaohui Jiang Rui Luo Dexing Zhou Feihu Zheng Liran Shi He Zhang Yong Wang Xiaodong Xu Renfang Zou Yujing Zhou Shuai Ren Xiaocheng Wang Haiqiang Sang |
| author_facet | He Lu Yaohui Jiang Rui Luo Dexing Zhou Feihu Zheng Liran Shi He Zhang Yong Wang Xiaodong Xu Renfang Zou Yujing Zhou Shuai Ren Xiaocheng Wang Haiqiang Sang |
| author_sort | He Lu |
| collection | DOAJ |
| description | Cardiovascular diseases (CVDs) continue to represent a major challenge to global health, highlighting the urgent need for innovative treatment approaches. As a growing interdisciplinary field, nanotechnology has demonstrated significant potential for clinical applications. Nanomedicine development primarily focuses on improving the disease diagnosis and treatment through leveraging the distinct characteristics of engineered nanoparticles (NPs) to detect disease markers or deliver therapeutics to specific targets. Specifically, cell membrane-coated NPs offer enhanced targeting, biostability, and immune evasion. A significant benefit associated with this technology lies in its capacity to retain the functional and intrinsic properties of the source cells. However, while each cell membrane possesses distinct characteristics, a single cell membrane may not always address complex functional requirements. By combining membranes from different cell types, it becomes possible to integrate diverse functionalities, resulting in a more comprehensive solution. In this review, we aim to explore recent advancements in the hybrid cell membrane-coated NPs (HM/NPs) and their potential applications for the treatment of CVDs. We highlight the mechanisms underlying HM/NPs and their utilization in the therapeutic management of CVDs. Additionally, we examine the potential for clinical translation and discuss the key challenges encountered in this process. |
| format | Article |
| id | doaj-art-dc52d16eb65645bd8d42e55dfb69ecc8 |
| institution | Kabale University |
| issn | 2590-0064 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials Today Bio |
| spelling | doaj-art-dc52d16eb65645bd8d42e55dfb69ecc82025-08-20T03:27:02ZengElsevierMaterials Today Bio2590-00642025-08-013310199210.1016/j.mtbio.2025.101992Engineered hybrid cell membrane nanosystems for treating cardiovascular diseasesHe Lu0Yaohui Jiang1Rui Luo2Dexing Zhou3Feihu Zheng4Liran Shi5He Zhang6Yong Wang7Xiaodong Xu8Renfang Zou9Yujing Zhou10Shuai Ren11Xiaocheng Wang12Haiqiang Sang13Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450066, China; Department of Cardiovascular, Fuwai Central China Cardiovascular Hospital, Henan Provincial People's Hospital, Zhengzhou, 451460, China; Department of Radiology, The People's Hospital of Jiawang District of Xuzhou, Xuzhou, Jiangsu, 221011, ChinaDepartment of Cardiovascular, Fuwai Central China Cardiovascular Hospital, Henan Provincial People's Hospital, Zhengzhou, 451460, ChinaDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450066, ChinaDepartment of Radiology, The People's Hospital of Jiawang District of Xuzhou, Xuzhou, Jiangsu, 221011, China; MOE Innovation Center for Basic Research in Tumor Immunotherapy, Hefei, Anhui, 230022, ChinaDepartment of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210029, China; Department of Ultrasonography, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221006, ChinaDepartment of Radiology, The People's Hospital of Jiawang District of Xuzhou, Xuzhou, Jiangsu, 221011, ChinaDepartment of Radiology, The People's Hospital of Jiawang District of Xuzhou, Xuzhou, Jiangsu, 221011, ChinaDepartment of Radiology, The People's Hospital of Jiawang District of Xuzhou, Xuzhou, Jiangsu, 221011, ChinaDepartment of Ultrasonography, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221006, ChinaNanjing Drum Tower Hospital, Drum Tower Clinical College, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, Jiangsu, 210008, ChinaDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450066, ChinaDepartment of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210029, China; Corresponding author.MOE Innovation Center for Basic Research in Tumor Immunotherapy, Hefei, Anhui, 230022, China; Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China; Corresponding author. MOE Innovation Center for Basic Research in Tumor Immunotherapy, Hefei, Anhui, 230022, China.Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450066, China; Corresponding author.Cardiovascular diseases (CVDs) continue to represent a major challenge to global health, highlighting the urgent need for innovative treatment approaches. As a growing interdisciplinary field, nanotechnology has demonstrated significant potential for clinical applications. Nanomedicine development primarily focuses on improving the disease diagnosis and treatment through leveraging the distinct characteristics of engineered nanoparticles (NPs) to detect disease markers or deliver therapeutics to specific targets. Specifically, cell membrane-coated NPs offer enhanced targeting, biostability, and immune evasion. A significant benefit associated with this technology lies in its capacity to retain the functional and intrinsic properties of the source cells. However, while each cell membrane possesses distinct characteristics, a single cell membrane may not always address complex functional requirements. By combining membranes from different cell types, it becomes possible to integrate diverse functionalities, resulting in a more comprehensive solution. In this review, we aim to explore recent advancements in the hybrid cell membrane-coated NPs (HM/NPs) and their potential applications for the treatment of CVDs. We highlight the mechanisms underlying HM/NPs and their utilization in the therapeutic management of CVDs. Additionally, we examine the potential for clinical translation and discuss the key challenges encountered in this process.http://www.sciencedirect.com/science/article/pii/S2590006425005629Hybrid cell membrane coatingBiomimetic nanoparticlesTargeted deliveryImmune evasionCardiovascular disease treatmentNanomedicine |
| spellingShingle | He Lu Yaohui Jiang Rui Luo Dexing Zhou Feihu Zheng Liran Shi He Zhang Yong Wang Xiaodong Xu Renfang Zou Yujing Zhou Shuai Ren Xiaocheng Wang Haiqiang Sang Engineered hybrid cell membrane nanosystems for treating cardiovascular diseases Materials Today Bio Hybrid cell membrane coating Biomimetic nanoparticles Targeted delivery Immune evasion Cardiovascular disease treatment Nanomedicine |
| title | Engineered hybrid cell membrane nanosystems for treating cardiovascular diseases |
| title_full | Engineered hybrid cell membrane nanosystems for treating cardiovascular diseases |
| title_fullStr | Engineered hybrid cell membrane nanosystems for treating cardiovascular diseases |
| title_full_unstemmed | Engineered hybrid cell membrane nanosystems for treating cardiovascular diseases |
| title_short | Engineered hybrid cell membrane nanosystems for treating cardiovascular diseases |
| title_sort | engineered hybrid cell membrane nanosystems for treating cardiovascular diseases |
| topic | Hybrid cell membrane coating Biomimetic nanoparticles Targeted delivery Immune evasion Cardiovascular disease treatment Nanomedicine |
| url | http://www.sciencedirect.com/science/article/pii/S2590006425005629 |
| work_keys_str_mv | AT helu engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT yaohuijiang engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT ruiluo engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT dexingzhou engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT feihuzheng engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT liranshi engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT hezhang engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT yongwang engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT xiaodongxu engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT renfangzou engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT yujingzhou engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT shuairen engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT xiaochengwang engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases AT haiqiangsang engineeredhybridcellmembranenanosystemsfortreatingcardiovasculardiseases |